REVIEW PAPER
Advancing Keratoconus Treatment. The Promise of Theranostic Technology
1
Department of Biomedical Sciences, University of Messina, Italy
2
Clinic of Ophthalmology, Medical College, Andrzej Frycz Modrzewski Krakow University
3
Vision Engineering Italy
4
Studio Italiano di Oftalmologia
Submission date: 2025-04-21
Final revision date: 2025-05-27
Acceptance date: 2025-06-11
Publication date: 2025-07-28
Medicine and Public Health 2024;2(2):1-8
KEYWORDS
TOPICS
ABSTRACT
Background:
Keratoconus, a progressive ectatic disorder of the cornea, presents significant challenges in clinical management due to its unpredictable progression and individualized nature. Advances in treatment modalities, particularly corneal cross-linking (CXL), have revolutionized the ability to halt disease progression. Yet, a significant gap remains in achieving personalized, outcome-driven interventions.
Material and methods:
Literature review
Results:
New personalized CXL approach based on theranostic biomarkers proved safe and effective in the treatment of KC and offers personalized approach to treat the disease.
Conclusions:
Theranostics technology integrated with advanced UV-A device for CXL procedure permits to deliver the precise therapeutical dose of riboflavin and personalized UV-A light amount for the photo-activation in the cornea. This real-time monitoring of riboflavin concentration in the cornea during CXL procedure permits to obtain better predictability of the final outcome on personal basis.
Keratoconus, a progressive ectatic disorder of the cornea, presents significant challenges in clinical management due to its unpredictable progression and individualized nature. Advances in treatment modalities, particularly corneal cross-linking (CXL), have revolutionized the ability to halt disease progression. Yet, a significant gap remains in achieving personalized, outcome-driven interventions.
Material and methods:
Literature review
Results:
New personalized CXL approach based on theranostic biomarkers proved safe and effective in the treatment of KC and offers personalized approach to treat the disease.
Conclusions:
Theranostics technology integrated with advanced UV-A device for CXL procedure permits to deliver the precise therapeutical dose of riboflavin and personalized UV-A light amount for the photo-activation in the cornea. This real-time monitoring of riboflavin concentration in the cornea during CXL procedure permits to obtain better predictability of the final outcome on personal basis.
© 2006-2025 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
